Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P100034/S045

Novocure GmbHs Optune Gio

Novocure, GmbH · Decision date Sep 18, 2026

MEDTECHLEDGER EXPLANATIONP100034/S045

What did the FDA approve?

FDA approved supplement S045 to PMA P100034 for Novocure GmbH's Optune Gio on September 18, 2026. The decision covers a location change for sterilization at SorVan Radiation, Ltd., Kiryat Soreq, POB 214, Yavne, 8180000, Israel. The device is classified as a low electric field tumor treatment stimulator under product code NZK, in the neurology specialty.

This supplement is a manufacturing site notice, not a new approval of the whole system. The statement identifies the changed item as the sterilizer location and does not report clinical data, a new indication, or independent evidence of safety or effectiveness. The source does not specify which components or quantities are sterilized at the new site, nor the sterilization method.

FDA approval order statement

Approval for a manufacturing site located at SorVan Radiation, Ltd., Kiryat Soreq, POB 214, Yavne, 8180000, Israel for sterilization.
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track No User Fee
Clinical specialty
Neurology
Decision date
Sep 18, 2026
FDA change category
Location Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P100034/S045
Regulatory pathway
PMA supplement
Product code
NZK
Decision code
APPR
Decision date
Sep 18, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Stimulator, low electric field, tumor treatment.

Product code
NZK
FDA device class
3

For the original device and its historical approval scope, see PMA P100034. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P100034 · Original PMA

    NOVOCURE LTD'S NOVOTTF-100A TREATMENT KIT

  2. P100034/S045 received

    Application receipt date recorded by FDA.

  3. P100034/S046 · Related supplement

    Optune HFE Transducer Arrays

  4. P100034/S045 · FDA decision

    Normal 180 Day Track No User Fee

Timeline entries are records held by MedtechLedger for P100034. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P100034

Product / regulatory recordCompanyPathwayDecision dateSource
Novocure, GmbHPMA approvalApr 8, 2011FDA
Novocure, GmbHPMA supplementSep 16, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Novocure, GmbH

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
Neuhofstrasse 21, Baar, 6340

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records